AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
08 Mar 2010 07:00 AM
RNS
Recentin Horizon III Study Re
05 Mar 2010 05:00 PM
RNS
Director/PDMR Shareholding
03 Mar 2010 04:30 PM
RNS
Director/PDMR Shareholding
01 Mar 2010 04:30 PM
RNS
Total Voting Rights
01 Mar 2010 12:00 PM
RNS
Update re Arrangements with M
26 Feb 2010 04:30 PM
RNS
Director/PDMR Shareholding
26 Feb 2010 04:30 PM
RNS
Director/PDMR Shareholding
24 Feb 2010 04:30 PM
RNS
Director/PDMR Shareholding
24 Feb 2010 04:30 PM
RNS
Director/PDMR Shareholding
23 Feb 2010 07:00 AM
RNS
UK tax settlement on transfer
23 Feb 2010 07:00 AM
RNS
Transaction in Own Shares
16 Feb 2010 07:00 AM
RNS
AZ in deal for rheumatoid art
09 Feb 2010 07:00 AM
RNS
FDA approves new indication f
01 Feb 2010 04:30 PM
RNS
Total Voting Rights
01 Feb 2010 04:00 PM
RNS
Director/PDMR Shareholding
28 Jan 2010 11:00 AM
RNS
Final Results (Part 3 of 3)
28 Jan 2010 11:00 AM
RNS
Final Results (Part 2 of 3)
28 Jan 2010 11:00 AM
RNS
Final Results (Part 1 of 3)
27 Jan 2010 04:00 PM
RNS
Director/PDMR Shareholding
27 Jan 2010 09:00 AM
RNS
Notice of Results
07 Jan 2010 07:00 AM
RNS
AZ agreement with Teva on US
04 Jan 2010 04:00 PM
RNS
Total Voting Rights
24 Dec 2009 07:01 AM
RNS
Complete Response Letter on M
23 Dec 2009 03:00 PM
RNS
Acquisition
16 Dec 2009 07:00 AM
RNS
FDA AdCom favourable vote on
11 Dec 2009 03:56 PM
RNS
FDA posts Crestor briefing ma
08 Dec 2009 04:00 PM
RNS
Holding(s) in Company
04 Dec 2009 07:00 AM
RNS
FDA clears Seroquel XR as add
03 Dec 2009 07:00 AM
RNS
AstraZeneca and Targacept lic
01 Dec 2009 04:00 PM
RNS
Total Voting Rights
19 Nov 2009 07:00 AM
RNS
US NDA submitted for Brilinta
02 Nov 2009 04:00 PM
RNS
Total Voting Rights
30 Oct 2009 03:30 PM
RNS
Director/PDMR Shareholding
29 Oct 2009 11:00 AM
RNS
3rd Quarter Results - Part 2
29 Oct 2009 11:00 AM
RNS
3rd Quarter Results - Part 1
28 Oct 2009 09:00 AM
RNS
Notice of Results
28 Oct 2009 07:00 AM
RNS
ZACTIMA
06 Oct 2009 04:30 PM
RNS
Holding(s) in Company
05 Oct 2009 02:39 PM
RNS
Onglyza EU marketing authoris
01 Oct 2009 04:00 PM
RNS
Total Voting Rights
28 Sep 2009 07:00 AM
RNS
US court affirms Seroquel sum
21 Sep 2009 11:00 AM
RNS
AstraZeneca development deal
08 Sep 2009 04:30 PM
RNS
Director/PDMR Shareholding
04 Sep 2009 04:19 PM
RNS
Publication of Prospectus
01 Sep 2009 03:00 PM
RNS
Director/PDMR Shareholding
01 Sep 2009 11:00 AM
RNS
Total Voting Rights
01 Sep 2009 07:00 AM
RNS
PLATO
26 Aug 2009 04:00 PM
RNS
Director/PDMR Shareholding
03 Aug 2009 07:00 AM
RNS
FDA approves Onglyza for type
31 Jul 2009 04:45 PM
RNS
Total Voting Rights
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings